MedTrace Logo

Efficacy and Safety of ATNC05 in Treatment of Atypical Facial Pain

NCT01920087 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2014-03-13

No results posted yet for this study

Summary

The purpose of the study is to test the efficacy of ATNC05 in the treatment of Atypical Facial Pain (AFP), also known as Persistent Idiopathic Facial Pain (PIFP). This research project targets patients with chronic constant facial pain and excludes patients with primarily paroxysmal pain.

Conditions

  • Atypical Facial Pain
  • Persistent Idiopathic Facial Pain
  • Atypical Trigeminal Neuralgia
  • Neuropathic Orofacial Pain
  • Neuropathic Facial Pain

Interventions

DRUG

ATNC05

Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.

DRUG

Placebo

Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.

Sponsors & Collaborators

  • Allodynic Therapeutics, Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2016-03-31
Completion
2016-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01920087 on ClinicalTrials.gov